Every year, approximately 800,000 people in the United States suffer a stroke. Of those who survive, roughly 80% experience some degree of motor impairment. Spinal cord injuries add another 18,000 cases annually. For these patients, regaining mobility and function depends on intensive, repetitive physical therapy — hundreds or thousands of repetitions of the same movements to retrain neural pathways.
The problem is that traditional physical therapy is constrained by human endurance — both the patient's and the therapist's. A therapist manually guiding a patient's leg through walking motions can sustain this for perhaps 20-30 minutes before fatigue sets in. A robotic exoskeleton can maintain the same precise, consistent movements for an hour or more, delivering the high-intensity, high-repetition therapy that produces the best outcomes.
Rehabilitation robots and exoskeletons have moved from research labs to clinical practice. In 2026, leading rehabilitation facilities worldwide use robotic systems as a standard component of stroke recovery, spinal cord injury rehabilitation, and orthopedic recovery programs. This guide covers the technology, the leading platforms, and what clinicians and administrators need to know.
How Rehabilitation Robots Work
Rehabilitation robots fall into two broad categories:
Clinic-based exoskeletons
These are wearable robotic devices that strap to the patient's legs (and sometimes torso and arms) and provide powered assistance for walking, standing, and other movements. A therapist supervises each session, adjusting the level of robotic assistance based on the patient's ability. The goal is "assist-as-needed" — the robot provides only enough support for the patient to complete the movement, encouraging active participation from the patient's own muscles and nervous system.
End-effector and platform systems
These are stationary devices where the patient stands on a platform or sits in a harness while robotic mechanisms move their limbs through therapeutic patterns. The Lokomat (by Hocoma) is the most recognized platform-based system. These systems excel in early-stage rehabilitation when the patient has minimal voluntary movement.
The distinction matters clinically: wearable exoskeletons provide a more natural gait pattern and can be used in varied settings (hallways, outdoor paths, home environments), while platform systems offer greater control and measurement precision in a clinical setting.
Leading Rehabilitation Robot Platforms
Ekso Bionics EksoNR 2
RoboScore: 81.5 / 100 | Target: Stroke and neurological rehabilitation (clinical)
The Ekso EksoNR 2 is a clinic-based exoskeleton designed specifically for neurological rehabilitation — stroke, spinal cord injury, traumatic brain injury, and multiple sclerosis. The EksoNR is FDA-cleared for clinical use and deployed in over 300 rehabilitation facilities worldwide.
The EksoNR 2's defining feature is its variable-assist technology. Rather than simply driving the patient's legs through a fixed walking pattern, the exoskeleton measures the patient's own force contribution at every step and adjusts its assistance accordingly. As the patient recovers strength and coordination, the robot provides less support — quantifiably progressing from full robotic assistance to patient-driven walking.
Key strengths:
- FDA-cleared for stroke, spinal cord injury, and acquired brain injury rehabilitation
- Variable-assist technology adapts to patient ability in real-time
- Extensive clinical evidence base — published studies in peer-reviewed journals
- SmartAssist software tracks patient progress across sessions with quantitative metrics
- Suitable for patients with a wide range of impairment levels
- Deployed in 300+ rehabilitation centers globally
Best suited for: Inpatient and outpatient rehabilitation centers treating neurological conditions. The EksoNR 2 is the standard choice for facilities building a robotic rehabilitation program from scratch.
ReWalk Personal 6
RoboScore: 78.8 / 100 | Target: Personal mobility for spinal cord injury (home and community)
The ReWalk Personal 6 occupies a different niche: it is designed for daily personal use by individuals with spinal cord injuries, not just clinical therapy sessions. The Personal 6 enables users with thoracic spinal cord injuries (T4-L5) to stand, walk, and navigate their homes and communities using a wearable exoskeleton and forearm crutches.
This distinction is important. The EksoNR 2 is a clinical tool used under therapist supervision. The ReWalk Personal 6 is a personal mobility device that the user operates independently after completing a training program. It represents a fundamentally different value proposition: not just rehabilitation, but restored daily mobility.
Key strengths:
- FDA-cleared for personal home and community use
- Enables independent standing and walking for eligible SCI patients
- Compact, relatively lightweight design (approximately 51 lbs)
- Battery provides 2-3 hours of continuous walking
- Training program prepares users for independent operation
- Shown to provide secondary health benefits (improved bone density, cardiovascular health, reduced spasticity)
Best suited for: Individuals with thoracic spinal cord injuries (T4-L5) who are medically stable and motivated to use the device for daily mobility. Requires adequate upper body strength and forearm crutch use.
Fourier Intelligence ExoMotion
RoboScore: 77.2 / 100 | Target: Multi-joint rehabilitation (clinical)
The Fourier ExoMotion is a modular rehabilitation robot system that addresses both upper and lower extremity rehabilitation. Unlike single-purpose exoskeletons, the ExoMotion platform can be configured for gait training, arm rehabilitation, hand therapy, and balance training — making it a versatile investment for rehabilitation departments that treat diverse patient populations.
Fourier's approach emphasizes gamification and patient engagement. The ExoMotion system connects to interactive games and virtual environments that make repetitive therapy exercises more engaging and motivating for patients — a significant factor in compliance and outcomes.
Key strengths:
- Modular platform covers upper extremity, lower extremity, and balance rehabilitation
- Gamified therapy interface improves patient engagement and compliance
- AI-driven adaptive difficulty adjusts to patient performance in real-time
- Comprehensive assessment tools generate quantitative progress reports
- Competitive pricing compared to Western-manufactured alternatives
- Growing clinical evidence base with studies across multiple conditions
Best suited for: Rehabilitation departments that need a versatile platform covering multiple body regions and conditions. Particularly attractive for facilities that want to offer robotic rehabilitation across stroke, orthopedic, and neurological populations.
Clinical Evidence and Outcomes
The evidence base for robotic rehabilitation has matured substantially. Key findings from recent systematic reviews and clinical trials:
Stroke rehabilitation: Robotic gait training combined with conventional therapy produces better walking outcomes than conventional therapy alone. Patients receiving robotic rehabilitation show 15-25% greater improvement in walking speed, endurance, and independence compared to control groups. The benefit is most pronounced in the subacute phase (1-6 months post-stroke).
Spinal cord injury: Exoskeleton-assisted walking training improves walking function in individuals with incomplete SCI. For complete SCI, robotic walking provides secondary health benefits including improved bone mineral density, cardiovascular conditioning, reduced spasticity, and improved bowel function — even when independent walking is not achieved.
Dose-response relationship: More repetitions produce better outcomes. Robotic therapy enables 2-3x more stepping repetitions per session compared to manual therapist-assisted training. This increased dosage is a primary mechanism for the observed clinical benefits.
Implementation Considerations
Space requirements
Clinic-based exoskeletons like the Ekso EksoNR 2 require a minimum of 15-20 feet of clear walking space for gait training. A dedicated 400-600 sq ft rehabilitation robotics room is ideal, allowing space for the exoskeleton, a parallel bar or overhead support system (for safety), and therapist movement. Platform-based systems like the Fourier ExoMotion may require less space but have specific floor loading requirements.
Staffing
Robotic rehabilitation sessions require a trained physical therapist. Current standards call for a 1:1 therapist-to-patient ratio during exoskeleton sessions. Therapists need manufacturer-provided training (typically 2-3 days for the EksoNR, 1-2 days for the ExoMotion) plus supervised clinical practice before operating independently.
Patient selection
Not every rehabilitation patient is a candidate for robotic therapy. General eligibility criteria include:
- Sufficient bone density to tolerate weight-bearing
- No uncontrolled spasticity that prevents safe fitting
- Adequate trunk control (varies by device)
- No significant contractures in the lower extremities
- Body weight and height within device specifications (typically 100-220 lbs, 5'0"-6'2")
Reimbursement
Insurance coverage for robotic rehabilitation varies significantly by payer, region, and diagnosis. Medicare covers robotic-assisted therapy when provided as part of a comprehensive rehabilitation program, but the robotic component is not separately billable — it is covered under the therapy session CPT codes. Many commercial insurers cover robotic rehabilitation for stroke and SCI under medical necessity criteria. The ReWalk Personal 6 has a more complex reimbursement pathway as a durable medical equipment purchase.
Cost and ROI for Rehabilitation Facilities
Equipment costs:
- Ekso EksoNR 2: $120,000-$150,000 (purchase) + $15,000-$25,000/year (service)
- ReWalk Personal 6: $85,000-$100,000 per unit (patient purchase/insurance)
- Fourier ExoMotion: $80,000-$120,000 (purchase) + $10,000-$15,000/year (service)
Revenue generation: A robotic rehabilitation program treating 6-8 patients per day generates $300,000-$500,000 in annual therapy revenue (at standard PT reimbursement rates). The equipment pays for itself within 6-12 months of full utilization.
Competitive advantage: In rehabilitation, reputation drives referrals. Facilities offering robotic rehabilitation attract higher-acuity patients, generate physician referrals, and differentiate themselves in an increasingly competitive market.
Frequently Asked Questions
Who is a candidate for robotic rehabilitation?
Candidacy depends on the specific device and diagnosis. For the Ekso EksoNR 2, candidates include stroke survivors, spinal cord injury patients, and individuals with traumatic brain injury or multiple sclerosis who have sufficient bone density and trunk stability. For the ReWalk Personal 6, candidates must have a thoracic spinal cord injury (T4-L5), adequate upper body strength, and be medically stable. A qualified rehabilitation physician and physical therapist should evaluate each patient individually.
How many sessions are needed to see results?
Clinical studies show measurable improvements after 12-20 sessions of robotic gait training for stroke patients. Significant functional gains typically require 30-40 sessions over 8-12 weeks. For spinal cord injury rehabilitation with the ReWalk Personal 6, the initial training program is typically 30-40 sessions before independent use. Ongoing therapy sessions may continue for months depending on recovery trajectory and patient goals.
Does insurance cover robotic rehabilitation?
Coverage varies by payer and diagnosis. Medicare covers robotic-assisted physical therapy when included in a comprehensive rehabilitation program — the therapy session is billed at standard PT rates. Many commercial insurers cover robotic rehabilitation for stroke and SCI with prior authorization. The ReWalk Personal 6 as a personal device has achieved some insurance coverage but reimbursement remains inconsistent. Patients should verify coverage with their specific insurer before beginning treatment.
Can robotic rehabilitation be done at home?
The ReWalk Personal 6 is specifically designed for home and community use after completing a clinical training program. Clinic-based devices like the EksoNR 2 and Fourier ExoMotion are designed for supervised clinical use and are not intended for unsupervised home therapy. Some upper-extremity rehabilitation robots offer home-use versions, but lower-extremity exoskeletons generally require clinical supervision due to fall risk.
Are rehabilitation robots replacing physical therapists?
No. Rehabilitation robots are tools that extend the therapist's capabilities. Every robotic rehabilitation session requires a licensed physical therapist to supervise, adjust parameters, monitor patient safety, and make clinical decisions. The robot handles the physically demanding repetitive component of therapy — guiding limbs through movements hundreds of times per session — while the therapist provides clinical judgment, motivation, manual techniques, and holistic care that a robot cannot replicate.